Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Table 5
Multivariate analysis of ≥15 letters gain from baseline at 6 months.
Predictors
(%)
OR (95% CI)
Baseline VA score
<20 letters
23
10 (43.5)
1.000
0.028
20–39 letters
56
25 (44.6)
0.688 (0.227–2.091)
40–59 letters
45
9 (20.0)
0.277 (0.081–0.944)
≥60 letters
20
2 (10.0)
0.107 (0.018–0.638)
Duration of neovascular AMD
<1 month
5
4 (80.0)
1.000
0.092
1–6.9 months
70
22 (31.4)
0.105 (0.010–1.113)
7–12 months
26
10 (38.5)
0.134 (0.012–1.542)
>12 months
31
5 (16.1)
0.047 (0.004–0.571)
ARMS2 rs10490924
GG
16
6 (37.5)
0.742 (0.190–2.897)
0.021
GT
44
21 (47.7)
1.000
TT
83
19 (22.9)
0.284 (0.114–0.706)
AMD: age-related macular degeneration; CI: confidence interval; OR: odds ratio; VA: visual acuity. Variables included in step 1 are age group, gender, baseline VA score, duration of neovascular AMD, ARMS2 rs10490924 genotype, and treatment regimen.
